Moffitt Cancer Center· @MoffittNews · X·· 2026-04-21Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
Body
Moffitt's Ahmad Tarhini, MD, PhD
@ATarhiniMDPhD
), stopped by our booth at #AACR26 to share preliminary findings from a Phase 1 trial evaluating a pan-RAF-MEK molecular glue in RAF- and RAS-mutant cancers. #MoffittAACR26
@AACR
Heat 17 · 10 likes · 1 reply · 6 reposts
Conference abstracts
CT129matched by 摘要号 CT129
Preliminary results from a Phase 1a/b dose-escalation and expansion trial of the pan-RAF-MEK molecular glue NST-628 in patients (pts) with advanced or refractory RAF, KRAS, and NRAS-mutant solid tumorsAhmad A. Tarhini, Monica Chen, Jia Liu, Varun Monga, Victoria Atkinson, Sarina A. Piha-Paul, Bartosz Chmielowski, Benjamin Herzberg, Charlotte Lemech, Prachi Bhave, Ganessan Kichenadasse, Gerald Falchook, Janice Mehnert, Andrae Vandross, Mohamad Salkeni, Meredith McKean, David Wages, Ann Marie Kennedy, Meagan B. Ryan, John Clark, Abdulaziz Nanah, Michael J. Fossler, Philip Komarnitsky, Igor Puzanov
Read the abstract →Source: Moffitt Cancer Center · x.com